Moteur de recherche d’entreprises européennes

Financement de l’UE (14 M €) : Pipeline de biomarqueurs translationnels de sécurité (TransBioLine) : Permettre le développement et la mise en œuvre de nouveaux biomarqueurs de sécurité dans les … Hor 01/02/2019 Programme de recherche et d'innovation de l'UE « Horizon »

Vue d’ensemble

Texte

Pipeline de biomarqueurs translationnels de sécurité (TransBioLine) : Permettre le développement et la mise en œuvre de nouveaux biomarqueurs de sécurité dans les essais cliniques et le diagnostic de maladies

Qualified biomarkers help to optimize drug development and patient safety, yet for the regulatory acceptance of safety biomarkers substantial sample sizes are needed to ensure adequate case and control numbers, and robust evidence sufficient for qualification. To address this challenge, a consortium of leading European research institutions and SMEs has been established. The consortium will generate exploratory and confirmatory data enabling regulatory qualification of new safety biomarkers for application in drug development; establish robust datasets on the DILI, DIKI, DIPI, DIVI and DINI biomarkers to enhance diagnosis of disease; develop and validate assays for new safety biomarkers; implement profiles of circulating miRNAs as tissue and mechanism specific diagnostic tool; have key safety biomarkers accepted as qualified drug development tools by EMA, FDA, and PMDA. Given the significant expertise available across the consortium, the group will be able to tackle the key challenges related to successful biomarker qualification. A key driving principle of the consortium is cross-linking via existing networks of top profile research institutions, as well as capitalizing on existing data and resources. The Consortium is embedded into a network of international research collaborations such as the Pro-Euro-DILI-registry, TransQST, eTRANSAFE, the i2b2 tranSMART Foundation, the CIOMS DILI working group, EPoS, LITMUS, and BBMRI. To optimize regulatory interaction, we intend to continue our successful collaboration with non-European consortia such as PSTC, the FNIH Biomarkers Consortium, and US DILIN. A key expected result of the consortium will be a “Safety Biomarker Factory”, regularly qualifying new markers, with an associated “Safety Biomarker Warehouse”, providing to the scientific community, industry, and patients detailed data and information, and knowledge across a large spectrum of advanced safety biomarkers.


ABX CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH 1 294 360 €
Assistance Publique Hopitaux de Paris 34 000 €
Charite - Universitaetsmedizin Berlin 1 386 194 €
Eli Lilly and Company Ltd. 0,00 €
F. Hoffmann-LA Roche AG 0,00 €
Information Technology FOR Translational Medicine (Ittm) SA 624 125 €
Institut de Recerca de L'Hospital de La Santa Creu i Sant Pau Fundacion 182 600 €
Janssen Pharmaceutica N.V. 0,00 €
Landspitali University Hospital 87 325 €
Liverpool University Hospitals NHS Foundation Trust 0,00 €
Ludwig-Maximilians-Universitaet Muenchen 400 000 €
Merck Sharp & Dohme Corp 0,00 €
Metaheps GmbH 124 804 €
MLM Medical Labs GmbH 604 800 €
Novartis Pharma AG 0,00 €
Pfizer Ltd. 0,00 €
Sanofi-Aventis Recherche & Developpement 0,00 €
Servicio Andaluz de Salud 188 946 €
Signatope GmbH 2 254 000 €
Synapse Research Management Partners SL 900 000 €
Tamirna GmbH 1 337 973 €
THE Critical Path Institute (C-Path) NON Profit Corporation 0,00 €
The University of Liverpool 943 125 €
The University of Nottingham 1 018 028 €
Universidad de Malaga 246 452 €
Universidad de Salamanca 69 500 €
Universitaet Bern 45 204 €
Universitat Zurich 2 187 562 €
Universiteit Leiden 3 000,00 €
University of Newcastle Upon Tyne 68 000 €

https://cordis.europa.eu/project/id/821283

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.